Medtronic plc (MDT) financials: revenue, earnings and cash flow
Fiscal 2017–2026 + TTM · from SEC filings · data as of November 13, 2026
Summary
Medtronic’s revenue went from $29.7B in fiscal 2017 to $36.4B in fiscal 2026, growth of about 2.3% a year.
Net income in fiscal 2026 was $4.8B, a net margin of 13.2%; the best year in this period was 2022 with $5.0B.
Over the twelve months to July 31, 2026, revenue was $37.5B and net income $5.2B.
Free cash flow was $5.4B in fiscal 2026 and positive in 10 of the 10 years shown.
The diluted share count fell 7% over the period (buybacks).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $37.5B | $36.4B | $33.5B | $32.4B | $31.2B | $31.7B | $30.1B | $28.9B | $30.6B | $30.0B | $29.7B |
| Gross profit | $24.4B | $23.6B | $21.9B | $21.1B | $20.5B | $21.5B | $19.6B | $19.5B | $21.4B | $20.9B | $20.4B |
| Operating income | $6.8B | $6.5B | $6.0B | $5.1B | $5.5B | $5.8B | $4.5B | $4.8B | $6.3B | $6.6B | $5.4B |
| Net income | $5.2B | $4.8B | $4.7B | $3.7B | $3.8B | $5.0B | $3.6B | $4.8B | $4.6B | $3.1B | $4.0B |
| EPS (diluted) | $4.07 | $3.73 | $3.61 | $2.76 | $2.82 | $3.73 | $2.66 | $3.54 | $3.41 | $2.27 | $2.89 |
| R&D | $2.9B | $2.9B | $2.7B | $2.7B | $2.7B | $2.7B | $2.5B | $2.3B | $2.3B | $2.3B | $2.2B |
| Revenue growth | — | +8.4% | +3.6% | +3.6% | −1.5% | +5.2% | +4.2% | −5.4% | +2.0% | +0.8% | +3.0% |
Cash flow
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $8.0B | $7.3B | $7.0B | $6.8B | $6.0B | $7.3B | $6.2B | $7.2B | $7.0B | $4.7B | $6.9B |
| Capital spending | -$1.9B | -$1.9B | -$1.9B | -$1.6B | -$1.5B | -$1.4B | -$1.4B | -$1.2B | -$1.1B | -$1.1B | -$1.3B |
| Free cash flow | $6.1B | $5.4B | $5.2B | $5.2B | $4.6B | $6.0B | $4.9B | $6.0B | $5.9B | $3.6B | $5.6B |
| Dividends paid | $3.6B | $3.6B | $3.6B | $3.7B | $3.6B | $3.4B | $3.1B | $2.9B | $2.7B | $2.5B | $2.4B |
| Buybacks | $1.2B | $1.0B | $3.2B | $2.1B | $645M | $2.5B | $652M | $1.3B | $2.9B | $2.2B | $3.5B |
| Stock-based pay | $496M | $457M | $429M | $393M | $355M | $359M | $344M | $297M | $290M | $344M | $348M |
Balance sheet
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $9.2B | $9.0B | $8.0B | $8.0B | $10.6B | $10.8B | $10.9B | $9.8B | $11.2B | $13.7B |
| Debt | — | $29.3B | $29.8B | $26.2B | $25.6B | $25.1B | $27.6B | $25.9B | $26.4B | $25.8B | $33.4B |
| Equity | — | $49.5B | $48.0B | $50.2B | $51.5B | $52.6B | $51.4B | $50.7B | $50.1B | $50.7B | $50.2B |
| Total assets | — | $93.0B | $91.7B | $90.0B | $90.9B | $91.0B | $93.1B | $90.7B | $89.7B | $91.4B | $99.9B |
| Shares (diluted) | 1.29B | 1.29B | 1.29B | 1.33B | 1.33B | 1.35B | 1.35B | 1.35B | 1.36B | 1.37B | 1.39B |
Margins and returns
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 65.0% | 65.0% | 65.3% | 65.3% | 65.7% | 68.0% | 65.2% | 67.4% | 70.0% | 69.8% | 68.7% |
| Operating margin | 18.1% | 17.8% | 17.8% | 15.9% | 17.6% | 18.1% | 14.9% | 16.6% | 20.5% | 22.2% | 18.1% |
| Net margin | 13.9% | 13.2% | 13.9% | 11.4% | 12.0% | 15.9% | 12.0% | 16.6% | 15.2% | 10.4% | 13.6% |
| FCF margin | 16.3% | 14.9% | 15.5% | 16.1% | 14.7% | 18.9% | 16.2% | 20.8% | 19.2% | 12.1% | 18.9% |
| ROIC | — | 6.5% | 6.4% | 5.1% | 5.0% | 6.8% | 5.3% | 4.9% | 7.3% | 4.7% | 5.6% |
| ROE | — | 9.7% | 9.7% | 7.3% | 7.3% | 9.6% | 7.0% | 9.4% | 9.2% | 6.1% | 8.0% |
Frequently asked questions
What is Medtronic’s annual revenue?
$36.4B in fiscal 2026 and $37.5B over the twelve months to July 31, 2026.
How much profit does Medtronic make?
Net income was $4.8B in fiscal 2026 (net margin 13.2%).
Is Medtronic’s revenue growing?
Yes: revenue rose 8.4% in fiscal 2026 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.